Trial · NCT04362527
Milrinone Infusion for VAsospam Treatment in Subarachnoid hemoRrhage
NCT04362527, Phase 3, Completed, University Hospital, Angers
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Milrinone Infusion for VAsospam Treatment in Subarachnoid hemoRrhage. Trials, record NCT04362527. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04362527
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Milrinone Infusion for VAsospam Treatment in Subarachnoid hemoRrhage
- NCT number
- NCT04362527
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 370 participants, actual
- Lead sponsor
- University Hospital, Angers
- Conditions
- Vasospasm
- Interventions
- Milrinone 1 Mg/mL Solution for Injection, Saline solution for injection
- First posted
- 2020-04-27
- Last updated
- 2026-03-09
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients with a good outcome at 3 months | 3 months | modified Rankin score ≤2 (0 = No symptoms, 1 = No significant disability. Able to carry out all usual activities, despite some symptoms, 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent, 6 = Death) |
| Secondary | Mortality rates in intensive care and in hospital | up to 6 months | To assess mortality rates in intensive care unit and in hospital and 6 months after aneurysm rupture. |
| Secondary | Modified Rankin Score at 3 and 6 months | 3 and 6 months | 0 = No symptoms, 1 = No significant disability. Able to carry out all usual activities, despite some symptoms, 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted, 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent, 6 = Death |
| Secondary | Glasgow outcome scale Extended at 3 and 6 months | up to 6 months | 1= Death, 2=Persistent vegetative state, 3=Sever disability, 4=Moderate disability, 5=Good recovery 2. Persistent vegetative state 3\. Severe disability 4. Moderate disability 5. Low disability |
| Secondary | EQ-5D | up to 6 months | Obtained by centralized telephone interview |
| Secondary | Evaluation of the radiologic effectiveness of the treatment | up to 14 days | Evaluation of the angiographic success according to angiographic CT-scannerwith blind analysis (coted as follows: light success, moderate success or important success) |
| Secondary | Evaluation of the radiologic effectiveness of the treatment | 3 months | Volume of infarcted areas at MRI control if available |
| Secondary | Evaluation of the hemodynamic tolerance of the treatment | 24 hours | need to introduce and/or increase doses of catecholamines by + 50% during the first 24 hours |
| Secondary | Evaluation of the metabolic tolerance of the treatment | up to 14 days | The occurrence of dysnatremia (\<135 mmol / L or\> 155 mmol / L), Daily diuresis. |
| Secondary | cerebral artery flow velocities | H0, H+2, H24+/-12h, H48+/-12h | Describe treatment-related variations in middle cerebral artery flow velocities. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04362527
GET https://conductscience.org/api/trials/v1/NCT04362527/registered